Global In-Vitro Diagnostics (IVD) Market
完整報告名稱與涵蓋範圍
Global In-Vitro Diagnostics (IVD) Market Competitive Landscape and Forecast till 2035
報告摘要
The Global In-Vitro Diagnostics (IVD) Market Competitive Landscape and Forecast till 2035 report profiles key global diagnostic corporations, evaluating competitive positioning, corporate strategies, and revenue performance through 2035. It assesses market concentration, product portfolios, and R&D pipelines.
Leading players are actively focusing on strategic acquisitions, molecular diagnostic innovations, platform automation, and expanding global distribution networks. Market growth faces challenges from rigorous regulatory scrutiny and intense price competition in generic testing reagents. Development of multi-analyte testing platforms serves as a key competitive differentiator.
授權報價
| Single User Price | $750 USD |
| Multi User Licence (up to 10 users) | $1,000 USD |
| Enterprisewide Price (Global Site License) | $1,250 USD |
目錄 Table of Contents
TABLE OF CONTENT
1.1 Introduction 11
1.2 Market Share Analysis, 2025 11
1.3 competitor dashboard 12
1.4 Public Players Stock Summary 13
1.5 Comparative Analysis: Key Players Financial 13
1.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 14
1.6.1 PRODUCT LAUNCH 14
1.6.2 PRODUCT APPROVAL 17
1.6.3 PRODUCT AVAILABILITY 18
1.6.4 PARTNERSHIP 19
1.6.5 AGREEMENT 20
1.6.6 SUSTAINABILITY 20
1.6.7 FACILITY EXPANSION 21
1.6.8 INVESTMENT 21
1.6.9 PRODUCT EXPANSION 22
2 COMPANY PROFILES 23
2.1 F. Hoffmann-La Roche Ltd 23
2.1.1 COMPANY OVERVIEW 23
2.1.2 FINANCIAL OVERVIEW 24
2.1.3 PRODUCTS OFFERED 24
2.1.4 KEY DEVELOPMENTS 26
2.1.5 SWOT ANALYSIS 28
2.1.6 KEY STRATEGIES 28
2.2 QIAGEN 29
2.2.1 COMPANY OVERVIEW 29
2.2.2 FINANCIAL OVERVIEW 30
2.2.3 PRODUCTS OFFERED 30
2.2.4 KEY DEVELOPMENTS 31
2.2.5 SWOT ANALYSIS 32
2.2.6 KEY STRATEGIES 33
2.3 Siemens Healthineers 34
2.3.1 COMPANY OVERVIEW 34
2.3.2 FINANCIAL OVERVIEW 35
2.3.3 PRODUCTS OFFERED 36
2.3.4 KEY DEVELOPMENTS 37
2.3.5 SWOT ANALYSIS 38
2.3.6 KEY STRATEGIES 38
2.4 Bio-Rad Laboratories, Inc 40
2.4.1 COMPANY OVERVIEW 40
2.4.2 FINANCIAL OVERVIEW 41
2.4.3 PRODUCTS OFFERED 41
2.4.4 KEY DEVELOPMENTS 43
2.4.5 SWOT ANALYSIS 44
2.4.6 KEY STRATEGIES 45
2.5 Thermo Fisher Scientific Inc 46
2.5.1 COMPANY OVERVIEW 46
2.5.2 FINANCIAL OVERVIEW 47
2.5.3 PRODUCTS OFFERED 47
2.5.4 KEY DEVELOPMENTS 48
2.5.5 SWOT ANALYSIS 49
2.5.6 KEY STRATEGIES 50
2.6 Sysmex Corporation 51
2.6.1 COMPANY OVERVIEW 51
2.6.2 FINANCIAL OVERVIEW 52
2.6.3 PRODUCTS OFFERED 52
2.6.4 KEY DEVELOPMENTS 54
2.6.5 KEY STRATEGIES 55
2.7 DiaSorin S.p.A 56
2.7.1 COMPANY OVERVIEW 56
2.7.2 FINANCIAL OVERVIEW 57
2.7.3 PRODUCTS OFFERED 58
2.7.4 KEY DEVELOPMENTS 59
2.7.5 KEY STRATEGIES 60
2.8 Randox Laboratories Ltd 61
2.8.1 COMPANY OVERVIEW 61
2.8.2 FINANCIAL OVERVIEW 61
2.8.3 PRODUCTS OFFERED 62
2.8.4 KEY DEVELOPMENTS 63
2.8.5 KEY STRATEGIES 63
2.9 Becton, Dickinson and Company 64
2.9.1 COMPANY OVERVIEW 64
2.9.2 FINANCIAL OVERVIEW 65
2.9.3 PRODUCTS OFFERED 66
2.9.4 KEY DEVELOPMENTS 66
2.9.5 KEY STRATEGIES 67
2.10 Illumina, Inc 68
2.10.1 COMPANY OVERVIEW 68
2.10.2 FINANCIAL OVERVIEW 69
2.10.3 PRODUCTS OFFERED 70
2.10.4 KEY DEVELOPMENTS 70
2.10.5 KEY STRATEGIES 71
3 DATA CITATIONS 72
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 PRODUCT LAUNCH 16
TABLE 2 PRODUCT APPROVAL 20
TABLE 3 PRODUCT AVAILABILITY 22
TABLE 4 PARTNERSHIP 23
TABLE 5 AGREEMENT 24
TABLE 6 SUSTAINABILITY 25
TABLE 7 FACILITY EXPANSION 26
TABLE 8 INVESTMENT 26
TABLE 9 PRODUCT EXPANSION 28
TABLE 10 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 30
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS 33
TABLE 12 QIAGEN: PRODUCTS OFFERED 38
TABLE 13 QIAGEN: KEY DEVELOPMENTS 39
TABLE 14 SIEMENS HEALTHINEERS: PRODUCTS OFFERED 45
TABLE 15 SIEMENS HEALTHINEERS: KEY DEVELOPMENTS 46
TABLE 16 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 51
TABLE 17 BIO-RAD LABORATORIES, INC.: KEY DEVELOPMENTS 53
TABLE 18 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 59
TABLE 19 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 59
TABLE 20 SYSMEX CORPORATION: PRODUCTS OFFERED 65
TABLE 21 SYSMEX CORPORATION: KEY DEVELOPMENTS 67
TABLE 22 DIASORIN S.P.A.: PRODUCTS OFFERED 72
TABLE 23 DIASORIN S.P.A.: KEY DEVELOPMENTS 73
TABLE 24 RANDOX LABORATORIES LTD.: PRODUCTS OFFERED 77
TABLE 25 RANDOX LABORATORIES LTD.: KEY DEVELOPMENTS 79
TABLE 26 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 83
TABLE 27 BECTON, DICKINSON AND COMPANY: KEY DEVELOPMENTS 84
TABLE 28 ILLUMINA, INC.: PRODUCTS OFFERED 89
TABLE 29 ILLUMINA, INC.: PRODUCTS OFFERED 89
LIST OF FIGURES
FIGURE 1 GLOBAL IN-VITRO DIAGNOSTICS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 13
FIGURE 2 COMPETITOR DASHBOARD: GLOBAL IN-VITRO DIAGNOSTICS MARKET 14
FIGURE 3 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW 30
FIGURE 4 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 34
FIGURE 5 QIAGEN: FINANCIAL OVERVIEW SNAPSHOT 38
FIGURE 6 QIAGEN: SWOT ANALYSIS 40
FIGURE 7 SIEMENS HEALTHINEERS: FINANCIAL OVERVIEW SNAPSHOT 44
FIGURE 8 SIEMENS HEALTHINEERS: SWOT ANALYSIS 48
FIGURE 9 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 51
FIGURE 10 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS 54
FIGURE 11 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 58
FIGURE 12 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 60
FIGURE 13 SYSMEX CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 65
FIGURE 14 DIASORIN S.P.A.: FINANCIAL OVERVIEW SNAPSHOT 71
FIGURE 15 BECTON, DICKINSON AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 82
FIGURE 16 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT 88
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們